Loading…
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
Schweizer, Michael T., Gulati, Roman, Yezefski, Todd, Cheng, Heather H., Mostaghel, Elahe, Haffner, Michael C., Patel, Radhika A., De Sarkar, Navonil, Ha, Gavin, Dumpit, Ruth, Woo, Brianna, Lin, Aaron, Panlasigui, Patrick, McDonald, Nerina, Lai, Michael, Nega, Katie, Hammond, Jeannette, Grivas, Petros, Hsieh, Andrew, Montgomery, Bruce, Nelson, Peter S., Yu, Evan Y.
Published in Prostate cancer and prostatic diseases (01.03.2023)
Published in Prostate cancer and prostatic diseases (01.03.2023)
Get full text
Journal Article
Loading…
The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis
Zhang, Xianlu, Zhang, Gejun, Wang, Jianfeng, Bi, Jianbin
Published in Frontiers in endocrinology (Lausanne) (10.02.2023)
Published in Frontiers in endocrinology (Lausanne) (10.02.2023)
Get full text
Journal Article
Loading…
Loading…
Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer
Kouiavskaia, Diana V, Berard, Carla A, Datena, Ellen, Hussain, Arif, Dawson, Nancy, Klyushnenkova, Elena N, Alexander, Richard B
Published in Journal of immunotherapy (1997) (01.07.2009)
Published in Journal of immunotherapy (1997) (01.07.2009)
Get more information
Journal Article